mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Biotechnology company
Slide background

Leading drug OС000459
Therapeutic focus: asthma and other respiratory diseases

Slide background

Currently preclinical and 1/2 clinical trials
have been successfully conducted and
shown a high efficacy and safety.

About

Eleventa is a Russian biotechnology company founded in 2012 to develop and commercialize innovative products for the treatment of asthma and other allergic and inflammatory respiratory diseases.

Load more

Product

OС000459, selective antagonist of CRTH2 receptors

Therapeutic focus: asthma and other respiratory diseases: allergic rhinitis, conjunctivitis, atopic dermatitis, and eosinophilic esophagitis.

Status: Phase 3 clinical trials.

Load more

 

© Eleventa, 2012—2020